| 生物活性 | |||
|---|---|---|---|
| 描述 | Evenamide (NW-3509) emerges as an orally active blocker of voltage-gated sodium channels (VGSCs), with a Ki of 0.4 µM, tailored for schizophrenia research. Its effectiveness spans across a wide array of rodent models for psychosis, mania, depression, and aggressiveness[1].[2]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
3.59mL 0.72mL 0.36mL |
17.96mL 3.59mL 1.80mL |
35.92mL 7.18mL 3.59mL |
| 参考文献 |
|---|